Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2045

1.

Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.

Minor DR, Moore D, Kim C, Kashani-Sabet M, Venna SS, Wang W, Boasberg P, O'Day S.

Oncologist. 2009 Oct;14(10):995-1002. doi: 10.1634/theoncologist.2009-0083. Epub 2009 Sep 23.

2.

Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.

O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS.

J Clin Oncol. 2009 Dec 20;27(36):6207-12. doi: 10.1200/JCO.2008.20.3075. Epub 2009 Nov 16.

PMID:
19917850
3.

Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.

Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U; American Joint Committee on Cancer Stage IV Melanoma.; EORTC 18951..

J Clin Oncol. 2007 Apr 20;25(12):1562-9.

PMID:
17443000
4.

Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.

O'Day SJ, Boasberg PD, Piro L, Kristedja TS, Wang HJ, Martin M, Deck R, Ames P, Shinn K, Kim H, Fournier P, Gammon G.

Clin Cancer Res. 2002 Sep;8(9):2775-81.

6.

Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.

Hoffmann R, Müller I, Neuber K, Lassmann S, Buer J, Probst M, Oevermann K, Franzke A, Kirchner H, Ganser A, Atzpodien J.

Br J Cancer. 1998 Oct;78(8):1076-80.

7.

Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.

Nowecki ZI, Rutkowski P, Kulik J, Siedlecki JA, Ruka W.

Br J Dermatol. 2008 Sep;159(3):597-605. doi: 10.1111/j.1365-2133.2008.08710.x. Epub 2008 Jul 4.

PMID:
18616789
8.

Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.

Bedikian AY, Johnson MM, Warneke CL, McIntyre S, Papadopoulos N, Hwu WJ, Kim K, Hwu P.

J Immunotoxicol. 2008 Apr;5(2):201-7. doi: 10.1080/15476910802131519.

PMID:
18569391
9.

Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma.

Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim K, Hwu WJ, McIntyre S, Hwu P.

Cancer Invest. 2008 Jul;26(6):624-33. doi: 10.1080/07357900802027073.

PMID:
18584354
10.

Prognostic factors in 1,521 melanoma patients with distant metastases.

Barth A, Wanek LA, Morton DL.

J Am Coll Surg. 1995 Sep;181(3):193-201.

PMID:
7670677
11.

Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.

Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N.

Cancer J Sci Am. 1997 Dec;3 Suppl 1:S9-15.

PMID:
9457387
12.
13.

Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma.

Franzke A, Probst-Kepper M, Buer J, Duensing S, Hoffmann R, Wittke F, Volkenandt M, Ganser A, Atzpodien J.

Br J Cancer. 1998 Jul;78(1):40-5.

14.

Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.

Hamberg AP, Korse CM, Bonfrer JM, de Gast GC.

Melanoma Res. 2003 Feb;13(1):45-9.

PMID:
12569284
15.

The natural history of resectable metastatic melanoma (Stage IVA melanoma).

Feun LG, Gutterman J, Burgess MA, Hersh EM, Mavligit G, McBride CM, Benjamin RS, Richman SP, Murphy WK, Bodey GP, Brown BW, Mountain CF, Leavens ME, Freireich EJ.

Cancer. 1982 Oct 15;50(8):1656-63.

16.

Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.

Wimmer I, Meyer JC, Seifert B, Dummer R, Flace A, Burg G.

Cancer Res. 1997 Nov 15;57(22):5073-6.

17.

The value of serum S-100beta and interleukins as tumour markers in advanced melanoma.

Vuoristo MS, Kellokumpu-Lehtinen P, Laine S, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E.

Melanoma Res. 2000 Jun;10(3):237-41.

PMID:
10890377
18.

Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors.

Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, Papadopoulos N, Benjamin RS.

Cancer. 1995 Nov 1;76(9):1665-70.

19.

Characteristics of metastasis as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.

Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Ku JH.

Tumori. 2007 Jan-Feb;93(1):68-74.

Supplemental Content

Support Center